Prolonged Activated Clotting Time after Protamine Administration Does Not Indicate Residual Heparinization after Cardiopulmonary Bypass in Pediatric Open Heart Surgery

Abstract

Background In open heart surgery, heparinization is commonly neutralized using an empirical heparin:protamine ratio ranging between 1:1 and 1:1.5. However, these ratios may result in protamine overdose that should be avoided for its negative side effects on the coagulation system. This study aimed to indicate the appropriate treatment for prolonged activated clotting time (ACT) after protamine administration following cardiopulmonary bypass (CPB) in pediatric open heart surgery by investigating the underlying reasons for it.

Methods Twenty-seven children (<10 kg) undergoing open heart surgery were included. Heparin was administered only before CPB (400 IU/kg) and in the pump priming volume for CPB (2,000 IU) and was neutralized by 1:1 protamine after CPB. The blood heparin concentration was measured using anti-Xa assay. ACT and blood concentrations of heparin, coagulation factors, thrombin–antithrombin complex, and prothrombin fragment 1 + 2 were assessed. A rotational thromboelastometry (ROTEM; Tem International GmbH, München, Bayern, Germany) was used to confirm the coagulation status and residual heparin after protamine administration.

Results Anti-Xa assay showed that there is no residual heparin in the blood after 1:1 protamine administration. Nevertheless, ACT (128.89 ± 3.09 seconds before heparin administration) remained prolonged (177.14 ± 5.43 seconds at 10 minutes after protamine, 182.00 ± 5.90 seconds at 30 minutes after protamine). The blood concentrations of coagulation factors were significantly lower than those before heparin administration (p < 0.01). The low FIBTEM MCF of ROTEM (4.43 ± 0.32 mm) at 10 minutes after protamine indicated low fibrinogen concentration.

Conclusion Prolonged ACT after heparin neutralization by 1:1 protamine administration does not necessarily indicate residual heparin, but low blood concentrations of coagulation factors should be considered as a reason as well. Accordingly, supply of coagulation factors instead of additional protamine should be considered.

Keywords

blood - coagulation/anticoagulation - cardiopulmonary bypass - congenital heart disease

Note

This study was presented at the 2014 Annual Meeting of the European Association of Cardiothoracic Anesthesiologists (EACTA)/14th International Congress of Cardiovascular Anesthesia (ICCVA), Florence, Italy, September 17–19, 2014.

• References

• 1 Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975; 69 (5) 685-689
• 2 Shanewise JS, Hug CC. Anesthesia for adult cardiac surgery. In: Miller RD, , ed. Anesthesia. 5th ed. New York: Churchill Livingstone; 2000: 1753-1805
• 3 Esposito RA, Culliford AT, Colvin SB, Thomas SJ, Lackner H, Spencer FC. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 85 (2) 174-185
• 4 Pi KD. Lack of correction between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 1983; 198 (1) 115
• 5 Despotis GJ, Summerfield AL, Joist JH , et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994; 108 (6) 1076-1082
• 6 Guzzetta NA, Monitz HG, Fernandez JD, Fazlollah TM, Knezevic A, Miller BE. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass. Anesth Analg 2010; 111 (1) 173-179
• 7 Ellison N, Ominsky AJ, Wollman H. Is protamine a clinically important anticoagulant? A negative answer. Anesthesiology 1971; 35 (6) 621-629
• 8 Mochizuki T, Olson PJ, Szlam F, Ramsay JG, Levy JH. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998; 87 (4) 781-785
• 9 Dunning J, Versteegh M, Fabbri A , et al; EACTS Audit and Guidelines Committee. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg 2008; 34 (1) 73-92
• 10 Michelson AD, MacGregor H, Barnard MR, Kestin AS, Rohrer MJ, Valeri CR. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost 1994; 71 (5) 633-640
• 11 Wolberg AS, Meng ZH, Monroe III DM, Hoffman M. A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma 2004; 56 (6) 1221-1228
• 12 Dirkmann D, Hanke AA, Görlinger K, Peters J. Hypothermia and acidosis synergistically impair coagulation in human whole blood. Anesth Analg 2008; 106 (6) 1627-1632
• 13 Newall F. Anti-factor Xa (anti-Xa) assay. Methods Mol Biol 2013; 992: 265-272
• 14 Kamath BS, Fozard JR. Control of heparinisation during cardiopulmonary bypass. Experience with the activated clotting time method. Anaesthesia 1980; 35 (3) 250-256
• 15 Akl BF, Vargas GM, Neal J, Robillard J, Kelly P. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1980; 79 (1) 97-102
• 16 Beholz S, Grubitzsch H, Bergmann B, Wollert HG, Eckel L. Hemostasis management by use of Hepcon/HMS: increased bleeding without increased need for blood transfusion. Thorac Cardiovasc Surg 1999; 47 (5) 322-327
• 17 Guzzetta NA, Bajaj T, Fazlollah T , et al. A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass. Anesth Analg 2008; 106 (2) 419-425 , table of contents
• 18 Noui N, Zogheib E, Walczak K , et al. Anticoagulation monitoring during extracorporeal circulation with the Hepcon/HMS device. Perfusion 2012; 27 (3) 214-220
• 19 Slight RD, Buell R, Nzewi OC, McClelland DB, Mankad PS. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2008; 22 (1) 47-52
• 20 Haizinger B, Gombotz H, Rehak P, Geiselseder G, Mair R. Activated thrombelastogram in neonates and infants with complex congenital heart disease in comparison with healthy children. Br J Anaesth 2006; 97 (4) 545-552
• 21 Miller BE, Guzzetta NA, Tosone SR, Levy JH. Rapid evaluation of coagulopathies after cardiopulmonary bypass in children using modified thromboelastography. Anesth Analg 2000; 90 (6) 1324-1330
• 22 Romlin BS, Wåhlander H, Berggren H , et al. Intraoperative thromboelastometry is associated with reduced transfusion prevalence in pediatric cardiac surgery. Anesth Analg 2011; 112 (1) 30-36
• 23 Horkay F, Martin P, Rajah SM, Walker DR. Response to heparinization in adults and children undergoing cardiac operations. Ann Thorac Surg 1992; 53 (5) 822-826
• 24 McDonald MM, Jacobson LJ, Hay Jr WW, Hathaway WE. Heparin clearance in the newborn. Pediatr Res 1981; 15 (7) 1015-1018
• 25 Slaughter TF, LeBleu TH, Douglas Jr JM, Leslie JB, Parker JK, Greenberg CS. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994; 80 (3) 520-526
• 26 Miyashita T, Nakajima T, Hayashi Y, Kuro M. Hemostatic effects of low-dose protamine following cardiopulmonary bypass. Am J Hematol 2000; 64 (2) 112-115
• 27 Nielsen VG. Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation. Ann Thorac Surg 2006; 81 (5) 1720-1727